Business
Regen BioPharma President Harry Lander Provides Mid-year Update on Company's Progress and Developments
Regen BioPharma President Harry Lander Provides Mid-year Update on Company's Progress and Developments.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma President Harry Lander Provides Mid-year Update on Company's Progress and Developments\n\n\n\n\n\nRegen BioPharma President Harry Lander Provides Mid-year Update on Company's Progress and Developments\nPR Newswire\nSAN DIEGO, July 13, 2016\n\n\n\nSAN DIEGO, July 13, 2016 /PRNewswire/ --\n\nRegen BioPharma, Inc.,(OTCQB: RGBP) and (OTCQB: RGBPP) President Harry Lander provided the following update for its shareholders:\n\nAs we pass the midway point of 2016, I would like to review Regen BioPharma's progress during the last 6 months and look forward at our plans for the rest of 2016.\n\nRegen BioPharma, Inc. is focused on developing innovative treatments using autologous cell therapies, immunotherapy and small molecule approaches to treat disorders in large and significant markets.\n\nScientific Development \n\nRegen has several major programs in different stages of development, with one FDA-cleared Investigational New Drug Application (\"IND\") and two INDs that have been submitted for clearance. The Company has an extensive patent portfolio, with 23 patents and applications, as well as an experienced and robust scientific team.\n\nTHERAPEUTIC PROGRAMS  \n\nProgram 1 - HemaXellerate: HemaXellerate is the Company's most advanced therapeutic asset, having received IND clearance in December 2015 to target aplastic anemia, a $2.4 billion market opportunity (MedTrack, 2016). In addition, the Company plans to file a separate IND, with clearance expected in Q4 2016, to target Chemotherapy-Induced Myelosuppression, a $12.9 billion market opportunity (MedTrack, 2016).\n\nHemaXellerate is the subject of an FDA-cleared IND and Phase I/II clinical trial that is intended to determine safety and potential efficacy of intravenously administered autologous SVF cells in patients with severe, immune suppressive refractory aplastic anemia. HemaXellerate is also currently being tested in a first-in-human proof of concept study ex-US, with no safety issues seen to date. This data will support further testing under a US IND. Management presently estimates that the investment needed to go through Phase I/II development will be approximately $1.0 million for aplastic anemia and $1.5 million for myelosuppression.\n\nRegen is targeting multi-billion dollar markets for both clinical indications using a novel and potentially...